Maintaining a healthy body composition is important to improve physical functioning and mobility in patients with axial spondyloarthritis receiving biologics, a new study indicated.
Bimekizumab is currently approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The rheumatology consultation may have been requested, but how can primary care practitioners help their patients who have suspected axial spondyloarthritis in the meantime?